Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Lyell Immunopharma (LYEL) Accumulated Depreciation & Amortization (2019 - 2025)

Lyell Immunopharma (LYEL) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $11.5 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization fell 41.22% to $11.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.5 million through Dec 2025, down 41.22% year-over-year, with the annual reading at $11.5 million for FY2025, 41.22% down from the prior year.
  • Accumulated Depreciation & Amortization hit $11.5 million in Q4 2025 for Lyell Immunopharma, down from $19.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $20.2 million in Q4 2023 to a low of $11.5 million in Q4 2025.
  • Historically, Accumulated Depreciation & Amortization has averaged $16.6 million across 5 years, with a median of $18.0 million in 2022.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 217.28% in 2021 and later crashed 41.22% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $13.6 million in 2021, then skyrocketed by 32.27% to $18.0 million in 2022, then grew by 12.38% to $20.2 million in 2023, then dropped by 3.06% to $19.6 million in 2024, then plummeted by 41.22% to $11.5 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for LYEL at $11.5 million in Q4 2025, $19.6 million in Q4 2024, and $20.2 million in Q4 2023.